RIPK1 and acute-on-chronic liver failure: It was discovered for the first time in human and rodent acute-on-chronic liver failure (ACLF) by Kondo et al. [112] that RIPK1-mediated cell death is critical, and it was also shown that inhibiting RIPK1 might be a new therapeutic method for preventing the progression of vulnerable individuals from ACLF.